Repligen on track for NDA filing for MRI pancreas agent, seeking priority review
This article was originally published in Scrip
Repligen's shares got a slight bump from the news that the company intends to submit its new drug application (NDA) later this summer on schedule for RG1068, a synthetic version of human secretin, as an agent to improve MRIs of the pancreas, with plans to seek a six-month priority review from the US FDA.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.